

Flucelvax® Quadrivalent Influenza Vaccine, 2018/2019 Season

Catalog No. NR-51698

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Melissa Ma, Fisher BioServices, Germantown, Maryland, USA and National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

Seqirus, Inc., Holly Springs, North Carolina, USA

Product Description:

NR-51698 is a subunit influenza virus vaccine prepared from virus propagated in Madin-Darby canine kidney (MDCK) cells. The virus was inactivated with β -propiolactone, disrupted by the detergent cetyltrimethylammonium bromide and purified through several process steps. Each of the four virus strains were produced and purified separately and then pooled to formulate the quadrivalent vaccine.

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 μ g each of the hemagglutinin (HA) antigens from influenza viruses A/Singapore/GP1908/2015 IVR-180 (H1N1) (an A/Michigan/45/2015-like virus), A/North Carolina/04/2016 (H3N2) (an A/Singapore/INFIMH-16-0019/2016-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus) and B/Singapore/INFIT-16-0610/2016 (a B/Phuket/3073/2013-like virus). Flucelvax Quadrivalent 0.5 mL pre-filled vaccine syringes contain no preservatives or antibiotics.

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2018-2019 season are now past their expiration dates (EXP. 31MAY2019).

Material Provided:

Each syringe contains 0.5 mL of virus suspension in phosphate-buffered saline.

Packaging/Storage:

NR-51698 is packaged in a 0.5 mL prefilled syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze. Protect from light.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Flucelvax® Quadrivalent Influenza Vaccine, 2018/2019 Season, NR-51698."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Grohskopf, L. A., et al. "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2018-2019 Influenza Season." MMWR Recomm. Rep. 67 (2018): 1-20. PubMed: 30141464.
- [WHO Recommendations for Influenza Vaccines](http://www.who.int/influenza/vaccines)

ATCC® is a trademark of the American Type Culture Collection.

